DOCSLIB.ORG

Rev. 26 Table 4: Pacs by Chemical Name (Mg/M3) (Pdf)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rev. 26 Table 4: Pacs by Chemical Name (Mg/M3) (Pdf) Table 4: Protective Action Criteria (PAC) Rev 26 based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are listed in alphabetical order and the values are presented in mg/m3. September 2010 Table 4 is an alphabetical list of the chemical substances and their corresponding PAC values in mass per unit volume (mg/m3). The conversion of ppm to mg/m3 was carried out assuming normal temperature and pressure, 25°C and 760 mm Hg. The final column in this table provides “Source of PACs” information. The columns presented in Table 4 provide the following information: Heading Definition No. The ordered numbering of the chemicals as they appear in this alphabetical listing Chemical Name The name of the chemical substance submitted to the PAC development team CASRN The Chemical Abstract Service Registry Number1 for this chemical TEEL-0 This is the threshold concentration below which most people will experience no adverse health effects. This value is always referred to as a TEEL-0 because AEGL-0 and ERPG-0 values do not exist. PAC-1 Based on the applicable AEGL-1, ERPG-1, or TEEL-1 value PAC-2 Based on the applicable AEGL-2, ERPG-2, or TEEL-2 value PAC-3 Based on the applicable AEGL-3, ERPG-3, or TEEL-3 value Source of PACs Technical comments are provided by the PAC development team, TEEL-0, PAC-1, indicating the source of the data used to derive PAC values. On-going PAC-2, PAC-3 efforts include reviewing, revising, and enhancing this information. Chemicals for which AEGLs are available have their chemical name, CASRN, and AEGL values displayed in a bolded and larger font. Chemicals for which ERPGs are available, but not AEGLs, have their chemical name, CASRN, and ERPG values displayed in a bolded font. Chemicals for which TEELs are available, but not AEGLs or ERPGs, have their chemical name, CASRN, and values displayed using a regular font. Additional information on PAC values and TEEL values and links to other sources of information is provided on the Subcommittee for Consequence Assessment and Protective Action (SCAPA) webpage at: http://orise.orau.gov/emi/scapa/teels.htm. 1 Information on the Chemical Abstract Service and CASRNs is provided at http://info.cas.org/. Introduction to PAC Table 4 – PAC Rev 26 – September 2010 September 2010 Table 4: Protective Action Criteria (PAC) Rev 26 (mg/m3) PAC Rev 26 Based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed in alphabetical order) PAC based on AEGLs, ERPGs, or TEELs (mg/m3) Source of PACs No. Chemical Name CASRN TEEL-0, PAC-1, PAC-2, PAC-3 TEEL-0 PAC-1 PAC-2 PAC-3 TEEL-1/3, TEEL-2/7, rat oral TDLo, and rat oral 1 Acacia; (Gum arabic) 9000-01-5 200 500 500 500 LD50 min exceeds 500 mg/m3 max 2 Acenaphthene 83-32-9 0.4 1.25 7.5 250 TEEL-1/3, TEEL-2/7, rat TCLo, rat ip LD50 TEEL-1/3, TEEL-2/7, rat TCLo, rat 3 Acenaphthylene 208-96-8 0.06 0.2 1.5 500 intraperitoneal exceeds 500 mg/m3 max 4 Acetaldehyde 75-07-0 40 81 486 1,510 TLV-C, AEGL-1, AEGL-2, AEGL-3 TEEL-1/3, TEEL-2/7, rabbit oral TDLo and rat 5 Acetamide 60-35-5 25 75 500 500 oral LD50 exceeds 500 mg/m3 max TEEL-1/3, TEEL-2/7, human oral TDLo, human 6 Acetanilide 103-84-4 0.4 1 7.5 50 oral LDLo 7 Acetic acid 64-19-7 12 12 86 610 PAC-1, ERPG-1, ERPG-2, ERPG-3 Acetic acid ethenyl ester, polymer with 1,1- 8 27360-07-2 10 30 50 250 Used PNOS default bis(ethenyloxy) butane and ethenol 9 Acetic acid, 2-propenyl ester 591-87-7 2 6 40 200 TEEL-1/3, TEEL-2/7, TEEL-3/5, rat 60-min LC50 TEEL-1/3, TEEL-2/7, TEEL-3/5, mouse oral 10 Acetic acid, lithium salt 546-89-4 12.5 35 250 500 LDLo 11 Acetic acid, manganese(2+) salt, tetrahydrate 6156-78-1 4.46 13.4 22.3 500 REL-TWA, REL-STEL, PEL-C, IDLH 12 Acetic acid, manganese(II) salt (2:1) 638-38-0 3.15 9.45 15.7 500 REL-TWA, REL-STEL, PEL-C, IDLH 13 Acetic anhydride 108-24-7 2.09 2.09 62.6 417 PAC-1, ERPG-1, ERPG-2, ERPG-3 14 Acetone 67-64-1 475 475 7,600 13,500 PAC-1, AEGL-1, AEGL-2, AEGL-3 15 Acetone thiosemicarbazide 1752-30-3 20 60 100 100 PAC-2/5, PAC-2*3/5, LOC, PAC-2 16 Acetone-d6 666-52-4 500 500 7,500 15,000 Used Acetone (CASRN 67-64-1) PAC values 17 Acetonitrile 75-05-8 21.8 21.8 537 1,120 PAC-1, AEGL-1, AEGL-2, AEGL-3 Chemicals with AEGLs: large, bolded font. ERPGs (but no AEGLs): bolded font. The "Source of PACs" column is under construction. 1 September 2010 Table 4: Protective Action Criteria (PAC) Rev 26 (mg/m3) PAC Rev 26 Based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed in alphabetical order) PAC based on AEGLs, ERPGs, or TEELs (mg/m3) Source of PACs No. Chemical Name CASRN TEEL-0, PAC-1, PAC-2, PAC-3 TEEL-0 PAC-1 PAC-2 PAC-3 18 Acetonitrile-d3 2206-26-0 20 20 600 1,250 Used Acetonitrile (CASRN 75-05-8) PAC values TLV-TWA, TLV-TWA, rat TCLo, mouse 240 min 19 Acetophenone 98-86-2 10 10 60 200 LC50 20 Acetoxytriphenylstannane 900-95-8 0.345 0.689 20 86.2 TLV-TWA, TLV-STEL, LOC, IDLH (Sn) 21 Acetyl bromide 506-96-7 1 3 20 100 TEEL-1/3, TEEL-2/7, TEEL-3/5, mouse ip LD50 Acetyl carbinol; (Acetol (1); 1-Hydroxy-2- 22 116-09-6 7.5 25 200 500 TEEL-1/3, TEEL-2/7, TEEL-3/5, rat oral LD50 propanone) 23 Acetyl chloride 75-36-5 0.0075 0.02 0.15 400 TEEL-1/3, TEEL-2/7, human TCLo, rat oral LD50 TEEL-1/3, TEEL-2/7, mouse ip TDLo, rat oral 24 Acetyl triethyl citrate 77-89-4 6 20 125 500 LD50 exceeds 500 mg/m3 max TEEL-1/3, TEEL-2/7, rat oral TDLo, mouse oral 25 Acetylaminofluorene, 2- 53-96-3 2.5 7.5 50 350 LD50 26 Acetylaminofluorenone, 2- 3096-50-2 0.75 2.5 15 75 TEEL-1/3, TEEL-2/7, rat oral TDLo, TEEL-2*5 27 Acetylene 74-86-2 125 350 2,500 6,000 TEEL-1/3, PAC-2/7, REL-C, human LCLo 28 Acrolein 107-02-8 0.0687 0.0687 0.229 3.21 PAC-1, AEGL-1, AEGL-2, AEGL-3 29 Acrylamide 79-06-1 0.03 15 60 60 TLV-TWA, PAC-3, PAC-3, IDLH Acrylamide, N,N'-methylenebisacrylamide 30 25034-58-6 10 30 50 250 Used PNOS default copolymer 31 Acrylic acid 79-10-7 4.42 4.42 135 530 PAC-1, AEGL-1, AEGL-2, AEGL-3 Acrylic acid polymers; (Acrylic polymer or 32 9003-01-4 10 30 200 500 T-3/105, T-3/35, T-3/5, rat oral LD50 resin) 33 Acrylonitrile 107-13-1 4 22 76 163 PEL-TWA,ERPG-1, ERPG-2, ERPG-3 34 Acrylyl chloride; (Acryloyl chloride) 814-68-6 0.15 0.5 0.899 35 T-2/5, T-2*3/5, LOC, mouse LC50 Chemicals with AEGLs: large, bolded font. ERPGs (but no AEGLs): bolded font. The "Source of PACs" column is under construction. 2 September 2010 Table 4: Protective Action Criteria (PAC) Rev 26 (mg/m3) PAC Rev 26 Based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed in alphabetical order) PAC based on AEGLs, ERPGs, or TEELs (mg/m3) Source of PACs No. Chemical Name CASRN TEEL-0, PAC-1, PAC-2, PAC-3 TEEL-0 PAC-1 PAC-2 PAC-3 35 Adamsite; (Phenarsazine chloride) 578-94-9 0.016 0.016 2.6 6.40 PAC-1, AEGL-1, AEGL-2, AEGL-3 36 Adipic acid 124-04-9 5 5 5 125 TLV-TWA, T-0, T-0, rat ip LD50 Adipic acid, diethylene glycol, trimethylolpropane, phthalic anhydride, 37 68609-57-4 10 30 50 250 Used PNOS default toluenediisocyanate polymer, isocyanate terminated 38 Adiponitrile 111-69-3 7.5 15 17 750 TLV-TWA, T-2, LOC, rat 240 min LC50 Aerosol, A-102; (Poly(oxy-1,2-ethanediyl), 39 alpha-(3-carboxy-1-oxo-3-sulfopropyl)-omega- 39354-45-5 125 400 500 500 T-3/105, T-3/35, T-3/5, rat oral LD50 (dodecyloxy)-, disodium salt) 40 Agar 9002-18-0 500 500 500 500 T-2/21, T-2/7, rat 4 week oral TDlo, rat oral LD50 Agarose, type VII (low gelling temperature); 41 9012-36-6 10 30 50 250 Used PNOS default (Sepharose) 42 Alamine 336 68814-95-9 20 60 500 500 T-3/105, T-3/35, T-3/5, rat LD50 43 Albumin (bovine) 9048-46-8 150 500 500 500 T-2/35, T-3/7, rat iv 90 day TDlo, rat iv LDlo 44 Alcohol oxidase 9073-63-6 10 30 50 250 Used PNOS default 45 Alcohols, C6-C12 (N.O.S.) 68603-15-6 10 30 50 250 Default TLV-TWA for chemical class Aldrin; (1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a- 46 hexahydro-1,4-endo,exo-5,8- 309-00-2 0.05 1.5 10 25 TLV-TWA, TEEL-2/7, LOC, IDLH dimethanonaphthalene) 47 Aldrithiol-2; (2,2'-Dithiodipyridine) 2127-03-9 10 30 50 250 Used PNOS default Aliquat 336; (Adogen 464; Quaternary 48 ammonium compounds, tri(C8-10)-alkylmethyl- 63393-96-4 30 75 500 500 T-3/105, T-3/35, T-3/5, rat LClo , chlorides) Alizarin; (1,2-Dihydroxyanthraquinone; Turkey TEEL-3/105, TEEL-3/35, TEEL-3/5, wild bird oral 49 72-48-0 1.25 4 25 125 red oil) LD50 Chemicals with AEGLs: large, bolded font.
Load more

Recommended publications
  • Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
    Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1.
    [Show full text]
  • Wastewater-Borne Exposure of Limnic Fish to Anticoagulant Rodenticides
    Water Research 167 (2019) 115090 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres Wastewater-borne exposure of limnic fish to anticoagulant rodenticides * Julia Regnery a, , Pia Parrhysius a, Robert S. Schulz a, Christel Mohlenkamp€ a, Georgia Buchmeier b, Georg Reifferscheid a, Marvin Brinke a a Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, Am Mainzer Tor 1, 56068 Koblenz, Germany b Unit Aquatic Ecotoxicology, Microbial Ecology, Bavarian Environment Agency, Demollstr. 31, 82407 Wielenbach, Germany article info abstract Article history: The recent emergence of second-generation anticoagulant rodenticides (AR) in the aquatic environment Received 18 June 2019 emphasizes the relevance and impact of aquatic exposure pathways during rodent control. Pest control Received in revised form in municipal sewer systems of urban and suburban areas is thought to be an important emission 12 September 2019 pathway for AR to reach wastewater and municipal wastewater treatment plants (WWTP), respectively. Accepted 13 September 2019 To circumstantiate that AR will enter streams via effluent discharges and bioaccumulate in aquatic or- Available online 14 September 2019 ganisms despite very low predicted environmental emissions, we conducted a retrospective biological monitoring of fish tissue samples from different WWTP fish monitoring ponds exclusively fed by Keywords: fl Bioaccumulation municipal ef uents in Bavaria, Germany. At the same time, information about rodent control in asso- Biocides ciated sewer systems was collected by telephone survey to assess relationships between sewer baiting Monitoring and rodenticide residues in fish. In addition, mussel and fish tissue samples from several Bavarian surface PBT-Substances waters with different effluent impact were analyzed to evaluate the prevalence of anticoagulants in Sewer baiting indigenous aquatic organisms.
    [Show full text]
  • Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-Target Organisms Katherine Horak U.S
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine Horak U.S. Department of Agriculture, [email protected] Penny M. Fisher Landcare Research Brian M. Hopkins Landcare Research Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Horak, Katherine; Fisher, Penny M.; and Hopkins, Brian M., "Pharmacokinetics of Anticoagulant Rodenticides in Target and Non- target Organisms" (2018). USDA National Wildlife Research Center - Staff Publications. 2091. https://digitalcommons.unl.edu/icwdm_usdanwrc/2091 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine E. Horak, Penny M. Fisher, and Brian Hopkins 1 Introduction The concentration of a compound at the site of action is a determinant of its toxicity. This principle is affected by a variety of factors including the chemical properties of the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route of exposure, and physiological properties of the organism. Many compounds have to undergo chemical changes, biotransformation, into more toxic or less toxic forms. Because of all of these variables, predicting toxic effects and performing risk assess- ments of compounds based solely on dose are less accurate than those that include data on absorption, distribution, metabolism (biotransformation), and excretion of the compound.
    [Show full text]
  • Some Rodenticidal Properties of Coumatetralyl
    J.Hyg.,Camb. (1969), 67, 311 311 Printed in Great Britain Some rodenticidal properties of coumatetralyl BY J. H. GREAVES AND PRISCILLA AYRES Infestation Control Laboratory, Ministry of Agriculture, Fisheries and Food, Tolworth, Surrey {Received 26 September 1968) INTRODUCTION Coumatetralyl (3-(a-tetralyl)-4-hydroxycoumarin), an anti-coagulant rodenti- cide developed by Farbenfabriken Bayer A.G., has been used extensively against rats in Germany (Schultze, 1965). Comparatively little information is available, however, concerning its rodenticidal properties. The present laboratory study was therefore undertaken to investigate the toxicity of the anti-coagulant to warfarin- resistant and warfarin-susceptible rats (Rattus norvegicus Berk.) and to compare its palatability with that of warfarin (3-(<x-acetonylbenzyl)-4-hydroxycoumarin). METHODS Wild rats, presumed not to be resistant to warfarin (NR rats) were caught in a Midlands refuse destructor and on a Surrey farm. Warfarin-resistant (WR) rats were trapped on farms in three different areas of Britain: Nottinghamshire (WR Notts), Gloucestershire (WR Glos) and the Salop-Montgomeryshire area (WR Welsh). Field investigations had shown that the rats on the Nottinghamshire and Gloucestershire farms could not be controlled with warfarin. All ten WR Glos rats used in tests with coumatetralyl had first been given, and had survived, un- restricted feeding for 6 days on 0-005 % warfarin in the laboratory and similarly all but six of the 23 WR Notts rats had first been given periods of from 3 to 6 days on warfarin. The 53 WR Welsh animals had survived either 6 days feeding on 0-005 % warfarin or a single subcutaneous injection of 200 mg./kg.
    [Show full text]
  • Heavy Rainfall Provokes Anticoagulant Rodenticides' Release from Baited
    Journal Pre-proof Heavy rainfall provokes anticoagulant rodenticides’ release from baited sewer systems and outdoor surfaces into receiving streams Julia Regnery1,*, Robert S. Schulz1, Pia Parrhysius1, Julia Bachtin1, Marvin Brinke1, Sabine Schäfer1, Georg Reifferscheid1, Anton Friesen2 1 Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, 56068 Koblenz, Germany 2 Section IV 1.2 Biocides, German Environment Agency, 06813 Dessau-Rosslau, Germany *Corresponding author. Email: [email protected] (J. Regnery); phone: +49 261 1306 5987 Journal Pre-proof A manuscript prepared for possible publication in: Science of the Total Environment May 2020 1 Journal Pre-proof Abstract Prevalent findings of anticoagulant rodenticide (AR) residues in liver tissue of freshwater fish recently emphasized the existence of aquatic exposure pathways. Thus, a comprehensive wastewater treatment plant and surface water monitoring campaign was conducted at two urban catchments in Germany in 2018 and 2019 to investigate potential emission sources of ARs into the aquatic environment. Over several months, the occurrence and fate of all eight ARs authorized in the European Union as well as two pharmaceutical anticoagulants was monitored in a variety of aqueous, solid, and biological environmental matrices during and after widespread sewer baiting with AR-containing bait. As a result, sewer baiting in combined sewer systems, besides outdoor rodent control at the surface, was identified as a substantial contributor of these biocidal active ingredients in the aquatic environment. In conjunction with heavy or prolonged precipitation during bait application in combined sewer systems, a direct link between sewer baiting and AR residues in wastewater treatment plant influent, effluent, and the liver of freshwater fish was established.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • CHAPTER 1 General Introduction
    CHAPTER 1 General Introduction Chapter 1 1.1 General Introduction Drugs are defined as chemical substances that are used to prevent or cure diseases in humans and animals. Drugs can also act as poisons if taken in excess. For example paracetamol overdose causes coma and death. Apart from the curative effect of drugs, most of them have several unwanted biological effects known as side effects. Aspirin which is commonly used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever and as an anti-inflammatory medication, may also cause gastric irritation and bleeding. Also many drugs, such as antibiotics, when over used develop resistance to the patients, microorganisms and virus which are intended to control by drug. Resistance occurs when a drug is no longer effective in controlling a medical condition.1 Thus, new drugs are constantly required to surmount drug resistance, for the improvement in the treatment of existing diseases, the treatment of newly identified disease, minimise the adverse side effects of existing drugs etc. Drugs are classified in number of different ways depending upon their mode of action such as antithrombotic drugs, analgesic, antianxiety, diuretics, antidepressant and antibiotics etc.2 Antithrombotic drugs are one of the most important classes of drugs which can be shortly defined as ―drugs that reduce the formation of blood clots‖. The blood coagulation, also known as haemostasis is a physiological process in which body prevents blood loss by forming stable clot at the site of injury. Clot formation is a coordinated interplay of two fundamental processes, aggregation of platelets and formation of fibrin.
    [Show full text]
  • Some Aspects of the Pharmacology of Oral Anticoagulants
    Some aspects of the pharmacology of oral anticoagulants The pharmacology of oral anticoagulants ls discussed with particular rejerence to data of value in the management of therapy. The importance of individual variability in response and drug interaction is stressed. Other effects of these agents which may have clinical utility are noted. William W. Coon, M.D., and Park W. Willis 111, M.D., Ann Arbor, Mich. The Departments of Surgery (Section of General Surgery) and Medicine, University of Michigan Medical School In the twenty-five years sinee the isola­ dividual struetural features but by a com­ tion of the hemorrhagie faetor in spoiled bination of several: molecular shape, in­ sweet clever," the gradually inereasing creased aetivity with 6 membered hetero­ utilization of oral antieoagulants for the eyclic rings with a substituent in position prevention and therapy of thromboembolie 8 and with a methoxyl rather than a free disease has made them one of the most hydroxl group. Also important is the dernon­ widely used groups of pharmacologic stration that levorotatory warfarin is seven agents. This review is restrieted to as­ times more aetive than its enantiomer.F" peets of the pharmaeology of these agents As Hunter and Shepherd'" have pointed whieh may be important to their proper out, the failure to obtain a precise cor­ clinieal utilization. relation between strueture and antieoagu­ lant aetivity is "not surprising in view of Relation of structure to function the influence of small struetural changes The oral antieoagulants have been di­ on sueh variables as solubility, rate of ab­ vided into four main groups on the basis sorption, ease of distribution, degree of of ehemieal strueture (Fig.
    [Show full text]
  • Potential Risks of Nine Rodenticides to Birds and Nontarget Mammals: a Comparative Approach
    UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460 OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES Potential Risks of Nine Rodenticides to Birds and Nontarget Mammals: a Comparative Approach July 2004 Office of Pesticides Programs Environmental Fate and Effects Division Prepared by: William Erickson, Biologist Environmental Risk Branch 2 Douglas Urban, Senior Biologist Environmental Risk Branch 3 Executive Summary This document presents the Agency’s assessment of potential risks to birds and nontarget mammals from 9 rodenticides, including 3 second-generation anticoagulants (brodifacoum, difethialone, bromadiolone), 3 first-generation anticoagulants (diphacinone, chlorophacinone, warfarin), and 3 non-anticoagulant compounds (zinc phosphide, bromethalin, cholecalciferol). These rodenticides are predominantly used to control commensal rats and mice in and around buildings, transport vehicles, and in sewers. Some, mainly zinc phosphide, chlorophacinone, and diphacinone, also have products registered for other outdoor uses against other rodent and small mammalian pests. A major concern in using rodenticides is that they are not selective to the target species; birds and nontarget mammals that feed on grain-based baits (pellets, meal, treated grains, wax blocks) or meat-based, vegetable, or fruit baits are potentially at risk. The available information from laboratory and pen studies, field studies, control programs, reported incidents, and toxicokinetics also indicates that a variety of avian and mammalian predators and scavengers are potentially at risk from consuming animals poisoned with some of these rodenticides. The assessment focuses on the potential primary and secondary risks to birds and nontarget mammals posed by applications of these 9 rodenticides (11 baits) to control rats and mice in and around buildings (commensal use) and in field and other outdoor settings to control various rodent and other small mammalian pests.
    [Show full text]
  • ( 12 ) United States Patent
    US010272083B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,272 , 083 B2 Hamdy et al. (45 ) Date of Patent: Apr . 30, 2019 (54 ) METHODS OF TREATING CHRONIC ( 56 ) References Cited LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LEUKEMIA USING A BTK U . S . PATENT DOCUMENTS INHIBITOR 7 ,459 ,554 B2 12 /2008 Dong et al . 7 , 825 , 118 B2 11/ 2010 Honigberg et al. (71 ) Applicant: Acerta Pharma B . V ., Oss (NL ) 7 , 960 ,396 B2 6 / 2011 Honigberg et al . 8 , 377 , 946 B1 2 / 2013 Chen et al . 8 ,658 ,794 B2 2 / 2014 deMan et al . (72 ) Inventors : Ahmed Hamdy , Santa Cruz , CA (US ) ; 9 , 290 ,504 B2 3 / 2016 Barf et al . Wayne Rothbaum , New York , NY 2006 / 0084654 A1 4 / 2006 Beck et al . (US ) ; Raquel Izumi, San Carlos , CA 2008 / 0076921 A1 3 / 2008 Honigberg et al. ( US ) ; Brian Lannutti, Solana Beach , 2011/ 0257203 A1 10 / 2011 Honigberg et al . CA (US ) ; Todd Covey , San Carlos , CA 2012 /0053189 Al 3 / 2012 Loury (US ) ; Roger Ulrich , Sammamish , WA 2012 / 0095026 A1 4 /2012 Honigberg et al. (US ) ; Dave Johnson , Aptos, CA (US ) ; 2012/ 0129821 A15 /2012 Honigberg et al . Tjeerd Barf, Ravenstein (NL ) ; Allard 2012 /0135944 A1 5 /2012 Honigberg et al . Kaptein , Zaltbommel (NL ) 2012 /0165328 A1 6 /2012 Honigberg et al . 2013 /0018032 AL 1 /2013 Chen et al . 2013 /0079327 A1 3 / 2013 Yamamoto et al . ( 73 ) Assignee : ACERTA PHARMA B . V . , Oss (NL ) 2013/ 0338172 A1* 12 / 2013 Smyth . .. .. CO7D 487/ 04 514 /262 . 1 ( * ) Notice: Subject to any disclaimer, the term of this 2014 / 0073593 Al 3 / 2014 Conklin et al.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]